Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

sitravatinib (MGCD516)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

BMS, BeiGene

Drug class:

Multi-tyrosine kinase inhibitor

Related drugs:

‹

›

PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	tislelizumab-jsgr + MGCD516 Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr + MGCD516 Sensitive : C2	tislelizumab-jsgr + MGCD516 Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr + MGCD516 Sensitive : C2
CBL mutation	Sarcoma	CBL mutation	Sarcoma	MGCD516 Sensitive: C3 – Early Trials MGCD516 Sensitive : C3	MGCD516 Sensitive: C3 – Early Trials MGCD516 Sensitive : C3
CBL mutation	Non Small Cell Lung Cancer	CBL mutation	Non Small Cell Lung Cancer	MGCD516 Sensitive: C3 – Early Trials MGCD516 Sensitive : C3	MGCD516 Sensitive: C3 – Early Trials MGCD516 Sensitive : C3
CBL mutation	Melanoma	CBL mutation	Melanoma	MGCD516 Sensitive: C3 – Early Trials MGCD516 Sensitive : C3	MGCD516 Sensitive: C3 – Early Trials MGCD516 Sensitive : C3
PD-L1 overexpression	Oral Cancer	PD-L1 overexpression	Oral Cancer	nivolumab + MGCD516 Sensitive: C3 – Early Trials nivolumab + MGCD516 Sensitive : C3	nivolumab + MGCD516 Sensitive: C3 – Early Trials nivolumab + MGCD516 Sensitive : C3